Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Small glutamine-rich tetratricopeptide repeat-containing protein beta (SGTB) is a co-chaperone protein characterized by a high proportion of glutamine residues and the presence of tetratricopeptide repeat (TPR) motifs, which are protein interaction domains. SGTB is highly homologous to its paralog SGTA and is believed to modulate the activity of heat shock proteins (HSP70/HSP90) and contribute to the protein quality control machinery in the cytoplasm. It is primarily expressed in human brain and testis and forms complexes involved in regulating protein folding, degradation, and cellular stress response. SGTB is not classified as a therapeutic target, nor has it been directly linked to major diseases or targeted by known drugs. Its main biological function is as a co-chaperone in protein quality control and folding processes, acting through interactions with molecular chaperones and proteostasis machinery.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Small glutamine-rich tetratricopeptide repeat-containing protein beta (SGTB).